ES2038692T3 - Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos. - Google Patents

Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.

Info

Publication number
ES2038692T3
ES2038692T3 ES198787810664T ES87810664T ES2038692T3 ES 2038692 T3 ES2038692 T3 ES 2038692T3 ES 198787810664 T ES198787810664 T ES 198787810664T ES 87810664 T ES87810664 T ES 87810664T ES 2038692 T3 ES2038692 T3 ES 2038692T3
Authority
ES
Spain
Prior art keywords
acids
alcanodiphosphonic
procedure
obtaining substituted
phosphonic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787810664T
Other languages
English (en)
Other versions
ES2038692T4 (es
Inventor
Knut A. Dr. Jaeggi
Leo Dr. Widler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4280350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2038692(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES2038692T3 publication Critical patent/ES2038692T3/es
Anticipated expiration legal-status Critical
Application granted granted Critical
Publication of ES2038692T4 publication Critical patent/ES2038692T4/es
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Control Of El Displays (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

LOS ACIDOS ALCANODIFOSFONICOS, EN PARTICULAR, ACIDOS HETEROARILALCANODIFOSFONICOS DE FORMULA (I), DONDE R1, REPRESENTA LOS GRUPOS INDICADOS EN LA DESCRIPCION, Y R2 ES HIDROGENO, HIDROXILO, AMINO, TIOALQUILO INFERIOR O HALOGENO, Y SUS SALES POSEEN PROPIEDADES REGULADORAS DEL METABOLISMO DEL CALCIO Y PUEDEN EMPLEARSE COMO MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON ALTERACIONES DEL METABOLISMO DEL CALCIO. SE OBTIENEN, POR EJEMPLO, A PARTIR DE UN COMPUESTO DE FORMULA (II) DONDE X1 REPRESENTA UN GRUPO FOSFONICO FUNCIONALMENTE MODIFICADO Y X2 REPRESENTA UN GRUPO FOSFONICO LIBRE O FUNCIONALMENTE MODIFICADO. EN DICHO COMPUESTO SE CONVIERTE X1, Y EN SU CASO, X2, EN EL GRUPO FOSFONICO LIBRE.
ES87810664T 1986-11-21 1987-11-16 Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos. Expired - Lifetime ES2038692T4 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH466686 1986-11-21
CH4666/86 1986-11-21

Publications (2)

Publication Number Publication Date
ES2038692T3 true ES2038692T3 (es) 1993-08-01
ES2038692T4 ES2038692T4 (es) 2012-02-10

Family

ID=4280350

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87810664T Expired - Lifetime ES2038692T4 (es) 1986-11-21 1987-11-16 Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.

Country Status (27)

Country Link
US (1) US4939130A (es)
EP (1) EP0275821B1 (es)
JP (1) JP2744238B2 (es)
KR (1) KR960010752B1 (es)
AT (1) ATE72816T1 (es)
AU (1) AU607722B2 (es)
CA (1) CA1338937C (es)
CY (1) CY1827A (es)
DD (1) DD270533A5 (es)
DE (2) DE10199052I1 (es)
DK (1) DK174098B1 (es)
ES (1) ES2038692T4 (es)
FI (1) FI87570C (es)
GR (1) GR3003895T3 (es)
HK (1) HK114894A (es)
HU (1) HU199150B (es)
IE (1) IE59816B1 (es)
IL (1) IL84497A (es)
LU (1) LU90838I2 (es)
MX (1) MX9427A (es)
NL (1) NL300058I2 (es)
NO (2) NO173446C (es)
NZ (1) NZ222610A (es)
PH (1) PH24345A (es)
PT (1) PT86167B (es)
SG (1) SG92194G (es)
ZA (1) ZA878698B (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
EP0636135A1 (en) * 1991-04-27 1995-02-01 Japat Ltd Triazole compounds
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
SG47603A1 (en) * 1992-05-29 1998-04-17 Procter & Gamble Pharma Thio-substitute nitrogen containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism
US5753634A (en) * 1992-05-29 1998-05-19 The Procter & Gamble Company Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
EP0646119B1 (en) * 1992-05-29 1998-07-15 PROCTER & GAMBLE PHARMACEUTICALS, INC. Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque
WO1993024496A1 (en) * 1992-05-29 1993-12-09 Procter & Gamble Pharmaceuticals, Inc. Sulfur-containing phosponate compounds for treating abnormal calcium and phosphate metabolism
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
ATE179329T1 (de) * 1992-06-30 1999-05-15 Procter & Gamble Pharma Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5880111A (en) * 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
IL115041A0 (en) * 1995-08-23 1995-12-08 Yissum Res Dev Co Novel bisphosphonates process for their preparation and pharmaceutical compositions containing them
PT854724E (pt) * 1995-09-29 2005-08-31 Novartis Ag Metodo de tratar a doenca navicular em cavalos
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
WO2000014095A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
EP1240174A2 (en) * 1999-12-22 2002-09-18 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US8052987B2 (en) * 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
SI1296689T1 (sl) 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
BR0209647A (pt) 2001-05-16 2004-07-27 Novartis Ag Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
DE60309887T2 (de) * 2002-07-30 2007-05-16 Novartis Ag Kombination von einem aromatasehemmer mit einem bisphosphonat
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
CA2497353C (en) * 2002-09-16 2012-08-28 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
NZ536273A (en) 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
EP1525207A2 (en) * 2003-02-27 2005-04-27 Teva Pharmaceutical Industries Limited Process for purification of zoledronic acid
CA2530193A1 (en) 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US20050049693A1 (en) * 2003-08-25 2005-03-03 Medtronic Vascular Inc. Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
KR20060058134A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
WO2005041899A2 (en) * 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
EP2206717B1 (en) 2003-12-23 2013-03-27 Alchymars S.p.A. A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2005063717A1 (en) * 2003-12-26 2005-07-14 Natco Pharma Limited An improved process for the preparation of zoledronic acid
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
JP2008522977A (ja) * 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
EP1832293A4 (en) * 2004-12-10 2009-01-07 Tmrc Co Ltd MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT
MX2007009848A (es) * 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100687A1 (en) * 2005-03-24 2006-09-28 Dabur Pharma Ltd. Disodium pamidronate aqueous formulation
US7872144B2 (en) * 2005-06-13 2011-01-18 Jubilant Organosys Limited Process for producing biphosphonic acids and forms thereof
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
BRPI0616081A2 (pt) * 2005-09-12 2011-06-07 Reddy S Lab Inc triidrato cristalino de ácido zoledrÈnico
MX2008009579A (es) * 2006-01-27 2008-09-25 Univ Virginia Metodo para el tratamiento de dolor neuropatico.
AU2007212193A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2007125521A2 (en) * 2006-05-02 2007-11-08 Ranbaxy Laboratories Limited Polymorphic form of zoledronic acid and processes for their preparation
EP2099741A2 (en) * 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007323618A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
WO2008064337A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
WO2008116133A1 (en) * 2007-03-21 2008-09-25 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
US20090082312A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched zoledronic acid
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
ES2386851T3 (es) 2007-11-30 2012-09-03 Novartis Ag Alquil (C2-C5)-imidazol-bisfosfonatos
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EA201001578A1 (ru) * 2008-04-04 2011-06-30 Новартис Аг Фармацевтическая композиция с бисфосфонатом
PL213599B1 (pl) * 2008-10-31 2013-03-29 Politechnika Gdanska Sposób otrzymywania kwasu [1-hydroksy-2-(1H-imidazol-1-ilo)-etylideno] bisfosfonowego
EP2192126B1 (en) 2008-11-26 2013-03-27 Synthon B.V. Process for making zoledronic acid
US20100130746A1 (en) * 2008-11-26 2010-05-27 Martin Kas Process for Making Zoledronic Acid
US20110257131A1 (en) * 2008-12-23 2011-10-20 Novartis Ag Phenylalkyl-imidazole-bisphosphonate compounds
EP2458996B1 (en) * 2009-07-31 2016-09-07 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
PT2473172E (pt) 2009-09-01 2015-06-25 Univ Duke Composições de bisfosfonato e métodos para o tratamento de insuficiência cardíaca
RU2415145C1 (ru) * 2009-09-15 2011-03-27 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения золедроновой кислоты
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
BR112012026098A2 (pt) 2010-04-16 2016-11-22 Novartis Ag métodos e composições para melhorar a osseointegração de implante.
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
HU230718B1 (hu) 2011-02-08 2017-11-28 Richter Gedeon Nyrt. Új eljárás dronsavak gyógyszeripari előállítására
CN102276650A (zh) * 2011-06-22 2011-12-14 苏州莱克施德药业有限公司 一种唑来膦酸的制备方法
CA2856030A1 (en) 2011-11-16 2013-05-23 Duke University Bisphosphonate compositions and methods for treating and/or reducing cardiac dysfunction
CN102617642B (zh) * 2012-02-24 2015-11-18 江苏省原子医学研究所 一种含2-乙基咪唑的双膦酸化合物及其制备方法和应用
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9012432B2 (en) 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
RU2725962C2 (ru) * 2020-02-12 2020-07-07 Акционерное Общество "Фарм-Синтез" Способ приготовления фармацевтической композиции на основе золедроновой кислоты в виде раствора для инфузий для лечения онкологических заболеваний и способ получения фармацевтической композиции на основе золедроновой кислоты в виде концентрата для приготовления раствора для инфузий для лечения онкологических заболеваний
CN114057648B (zh) * 2020-07-30 2024-02-20 常州方圆制药有限公司 一种唑来膦酸中间体杂质的制备方法
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3203307A1 (de) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Phosphonate, und diese enthaltende pharmazeutische verbindungen
EP0084822B1 (de) * 1982-01-27 1986-01-08 Schering Aktiengesellschaft Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate
DE3203308A1 (de) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
NO874856D0 (no) 1987-11-20
MX9427A (es) 1993-12-01
NO2001015I2 (no) 2004-10-11
AU8145387A (en) 1988-05-26
NL300058I2 (nl) 2002-02-01
DE3776880D1 (de) 1992-04-02
HK114894A (en) 1994-10-27
DK609587A (da) 1988-05-22
KR880006204A (ko) 1988-07-22
DK609587D0 (da) 1987-11-20
IE873148L (en) 1988-05-21
SG92194G (en) 1995-04-28
FI87570C (fi) 1993-01-25
NO874856L (no) 1988-05-24
ZA878698B (en) 1988-05-23
EP0275821B1 (de) 1992-02-26
US4939130A (en) 1990-07-03
IL84497A (en) 1994-10-21
LU90838I2 (fr) 2001-11-19
EP0275821A1 (de) 1988-07-27
PT86167A (en) 1987-12-01
AU607722B2 (en) 1991-03-14
NL300058I1 (nl) 2001-12-01
NZ222610A (en) 1990-09-26
FI875096A7 (fi) 1988-05-22
NO173446C (no) 1993-12-15
FI87570B (fi) 1992-10-15
ATE72816T1 (de) 1992-03-15
HU199150B (en) 1990-01-29
ES2038692T4 (es) 2012-02-10
CY1827A (en) 1995-12-01
IL84497A0 (en) 1988-04-29
PT86167B (pt) 1990-08-31
FI875096A0 (fi) 1987-11-18
GR3003895T3 (es) 1993-03-16
DE10199052I1 (de) 2002-01-10
PH24345A (en) 1990-06-13
JP2744238B2 (ja) 1998-04-28
CA1338937C (en) 1997-02-25
NO173446B (no) 1993-09-06
JPS63150291A (ja) 1988-06-22
KR960010752B1 (ko) 1996-08-08
DK174098B1 (da) 2002-06-17
HUT46330A (en) 1988-10-28
IE59816B1 (en) 1994-04-06
DD270533A5 (de) 1989-08-02

Similar Documents

Publication Publication Date Title
ES2036194T3 (es) Derivados n-fosfonilmetoxialquilicos de bases de pirimidina y purina, metodos para su preparacion y composiciones farmaceuticas basadas en ellos, con actividad antivirica.
ES2043622T3 (es) Acido 1-hidroxi-3-(n-metil-n-propilamino) propan-1,1-difosfonico, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos.
ES2194835T3 (es) Agentes antitromboticos a base de tripeptidos.
GT198400014A (es) Mejoras en o relativas a fenetanolaminas.
ES2169023T3 (es) Nueva 1alfa-hidroxi vitaminada d4 y nuevos intermedios y analogos.
ES2083464T3 (es) Compuestos heterociclicos.
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
ES480028A1 (es) Procedimiento para la preparacion de reactivos para la de- terminacion de amilasa.
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
ES2016588B3 (es) Proceso para producir polimero alfa olefinico.
ES8700232A1 (es) Un procedimiento para producir 1a,25-dihidroxi-26,27-dime- tilcolecalciferol
ES8103027A1 (es) Un procedimiento para la preparacion de un polipeptido
ES8706700A1 (es) Procedimiento para preparar un derivado de cefalosporina.
ES2074431T3 (es) Un procedimiento para la sintesis de amicacina.
ES8706692A1 (es) Un metodo para preparar nuevos derivados de cefem
FI864246A0 (fi) N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat.
DK482185D0 (da) Peptider, deres fremstilling og anvendelse som laegemidler
ES2061964T3 (es) Compuestos de diamina.
ATE24526T1 (de) Herstellung von photohaertbaren zusammensetzungen.
NO176144C (no) Nye difosfonsyreforbindelser
ES2044970T3 (es) Procedimiento para la obtencion de compuestos hidrogenados del acido 1-benzooxacicloalquil-piridincarboxilico.
ES2032582T3 (es) Procedimiento para preparar derivados de la oxima del 1,2,5,6,-tetrahidropiridin -3-carboxialdehido.
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
ES2051954T3 (es) 2-aminotiazoles substituidos.
BR8107668A (pt) Processo para a producao de compostos,bem como composicoes de vedacao e composicoes de colagem a base desses compostos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 275821

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: ACIDO ZOLEDRONICO (ZOMETA)

Spc suppl protection certif: C200100028

Filing date: 20010901

SPCG Supplementary protection certificate granted

Free format text: ACIDO ZOLEDRONICO (ZOMETA).

Spc suppl protection certif: C200100028

Filing date: 20010901

Expiry date: 20121116

Effective date: 20040614